Dimensional Fund Advisors LP Has $529,000 Stake in Sanara MedTech Inc. (NASDAQ:SMTI)

Dimensional Fund Advisors LP boosted its stake in shares of Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) by 116.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,925 shares of the company's stock after acquiring an additional 8,567 shares during the period. Dimensional Fund Advisors LP owned 0.18% of Sanara MedTech worth $529,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Marshall Wace LLP acquired a new stake in shares of Sanara MedTech in the 4th quarter valued at $1,005,000. Barclays PLC boosted its holdings in shares of Sanara MedTech by 12.1% in the 4th quarter. Barclays PLC now owns 6,423 shares of the company's stock valued at $213,000 after purchasing an additional 692 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Sanara MedTech by 152.9% in the 4th quarter. Renaissance Technologies LLC now owns 35,400 shares of the company's stock valued at $1,175,000 after purchasing an additional 21,400 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Sanara MedTech by 53.9% in the 4th quarter. Wells Fargo & Company MN now owns 1,893 shares of the company's stock valued at $63,000 after purchasing an additional 663 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Sanara MedTech by 234.5% in the 4th quarter. JPMorgan Chase & Co. now owns 13,574 shares of the company's stock valued at $451,000 after purchasing an additional 9,516 shares in the last quarter. Institutional investors own 8.10% of the company's stock.

Sanara MedTech Price Performance

Shares of SMTI stock traded down $0.03 during trading hours on Thursday, reaching $30.99. The company's stock had a trading volume of 15,133 shares, compared to its average volume of 26,168. The firm's 50 day simple moving average is $30.98 and its 200-day simple moving average is $33.39. The company has a market capitalization of $275.44 million, a price-to-earnings ratio of -31.30 and a beta of 1.38. Sanara MedTech Inc. has a fifty-two week low of $25.86 and a fifty-two week high of $39.08. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Sanara MedTech had a negative net margin of 10.71% and a negative return on equity of 19.86%. The firm had revenue of $23.43 million for the quarter, compared to analyst estimates of $23.48 million. Sell-side analysts forecast that Sanara MedTech Inc. will post -1.1 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on SMTI. HC Wainwright raised their target price on Sanara MedTech from $51.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, May 15th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $46.00 target price on shares of Sanara MedTech in a report on Wednesday, March 26th.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.